About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 85 record(s)
Req # A-2022-001495
Adverse Drug Reactions (ADRs). Report numbers: E2B_05172969, E2B_05223762, 001001275, E2B_05627878, E2B_05766145, E2B_05797168, E2B_04659086, E2B_04737772, 000998122, E2B_05422984.Organization: Health Canada
May 2023
Req # A-2022-001513
Adverse Drug Reactions (ADRs) for ALENDRONIC ACID. Report numbers: E2B_01803976, E2B_01806955, E2B_01839494, E2B_01895557, 000721014, E2B_01835937, E2B_02275602, E2B_01898967, 000720995, E2B_02035743.Organization: Health Canada
May 2023
Req # A-2022-001517
Adverse Drug Reactions (ADRs) for VEDOLIZUMAB. Report numbers: E2B_05980473, E2B_06029464. ADRs for ONDANSETRON. Report numbers: E2B_05986311, E2B_05988217, E2B_05974379, E2B_05970800. ADR for PANTOLOC. Report number: 001022041. ADRs for MEZAVANT.…Organization: Health Canada
May 2023
Req # A-2022-001519
Adverse Drug Reactions (ADRs) for MESALAZINE. Report numbers: E2B_06001907, 001022481, E2B_05992336, E2B_05996880, E2B_05975434, E2B_05992300, E2B_06029464, E2B_06004192, 001022980, 001025517.Organization: Health Canada
May 2023
Req # A-2022-001521
Adverse Drug Reactions (ADRs) for VYVANSE. Report numbers: 001022362, E2B_06007689, 001021585, 001022523. ADRs for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_05981092, E2B_06009474, E2B_05986973, E2B_06029786. ADR for GAMMAGARD LIQUID.…Organization: Health Canada
May 2023
Req # A-2022-001543
Adverse Drug Reactions (ADRs). Report numbers: E2B_05995344, E2B_05998688, E2B_06025434.Organization: Health Canada
May 2023
Req # A-2022-001558
Adverse Drug Reactions (ADRs) for PATIROMER. Report numbers: E2B_06052509, E2B_06052511, E2B_06074727. ADR for VELPHORO. Report number: 001023533. ADR for ABILIFY. Report number: 001023608.Organization: Health Canada
May 2023
Req # A-2022-001582
Adverse Drug Reactions (ADRs). Report numbers: 001021984, E2B_05992367, E2B_05977360, 001023218, 001021985.Organization: Health Canada
May 2023
Req # A-2022-001603
Adverse Drug Reactions (ADRs). Report numbers: E2B_06029094, E2B_06028638, E2B_06009141, E2B_05972656, E2B_05982908, 001024270, E2B_06015264, 001022060, E2B_05979018, E2B_05977730.Organization: Health Canada
May 2023
Req # A-2022-001627
Adverse Drug Reactions (ADRs). Report numbers: E2B_05494677, E2B_06037946.Organization: Health Canada
May 2023